OraSure

OraSure Technologies (OSUR) is a mission-driven diagnostics company focused on decentralizing healthcare through a portfolio of non-invasive testing and sample collection platforms. Its strategy has been built on internal innovation and strategic acquisitions, including DNA Genotek (sample management), BioMedomics (point-of-care rapid tests), and Sherlock Biosciences (next-gen molecular platforms). This has created a comprehensive ecosystem from sample to result, targeting infectious diseases, genetic conditions, and research applications. The company aims to improve healthcare access, quality, and value by empowering individuals and providers with actionable diagnostic insights.

A synergistic portfolio of diagnostic platforms including non-invasive sample collection/stabilization (oral fluid, saliva), lateral flow rapid tests, and next-generation instrument-free molecular platforms (INSPECTR™ synthetic biology and SHERLOCK™ CRISPR-based).

OraSure competes in distinct segments: against large players like Abbott in rapid POC tests, with differentiation in oral fluid; as a niche leader in molecular sample collection via DNA Genotek; and in the future, against CRISPR/molecular startups in instrument-free diagnostics. Its integrated sample-to-result strategy is a key differentiator.